^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Baituowei (goserelin acetate sustained-release microspheres for injection)

    i
    Other names: LY01005, LY 01005, LY-01005
    Associations

    News

    Trials
    Company:
    BeOne Medicines, Luye Group
    Drug class:
    GnRH stimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    Observational Study on the Injection Experience and Quality of Life of Breast Cancer Patients After Switching from Goserelin Acetate Sustained-Release Implants to Injectable Goserelin Microspheres (ChiCTR2500103194)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Dalian Medical University; No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province
    New P4 trial • HEOR
    |
    ER (Estrogen receptor)
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    6ms
    Goserelin Extended-Release Microspheres versus Sustained-Release Implant in Prostate Cancer: Real-World Evidence on Efficacy and Safety (ChiCTR2500100634)
    P4, N=50, Not yet recruiting, Aerospace Center Hospital; Aerospace Center Hospital
    New P4 trial • HEOR • Real-world evidence
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    8ms
    Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study (clinicaltrials.gov)
    P=N/A, N=400, Active, not recruiting, Qianfoshan Hospital
    New trial • HEOR • Real-world evidence
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    over1year
    To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial
    |
    goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)
    over2years
    Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial. (PubMed, Chin Med J (Engl))
    LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.
    P3 data • Journal • Head-to-Head
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    over2years
    Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P1, N=23, Completed, Luye Pharma Group Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    over2years
    Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P3, N=188, Completed, Luye Pharma Group Ltd. | Recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor)
    |
    tamoxifen • goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)
    4years
    Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P3; N=188; Recruiting; Sponsor:Luye Pharma Group Ltd.
    New P3 trial • Clinical
    |
    ER (Estrogen receptor)
    |
    goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)